Moximed said that surgeons have implanted its Calpyso knee unloading system in the first osteoarthritis patient in its U.S. clinical trial. The Calypso is designed to work like a shock absorber for the knee by restoring a more normal load balance within the joint. It may help prevent or delay total knee replacement, according to […]
These medtech companies raised the most VC last year
Perhaps there’s a ray of hope that venture capital funding is recovering a bit for the medical device industry. VC firms invested more than $2.8 billion in 2017, an increase of more than $647 million from 2016, according to the MoneyTree Report from PricewaterhouseCoopers (PwC) and CB Insights. There were a total 229 deals involving […]
Moximed closes $50m Series C
California orthopedic device developer Moximed said today it raised $50 million in a Series C round of financing. The round was joined by newly invested Advent Life Sciences and Future fund and existing investors NEA, Morgenthaler Ventures, Gilde Healthcare, GBS Venture Partners and Vertex Healthcare. “This financing round is timely, as we are completing the primary […]
Moximed launches IDE trial of Atlas unicompartmental knee
California orthopedic device developer Moximed said today it enrolled the 1st patient in an FDA approved investigational device exemption trial of its next-gen Atlas unicompartmental unloading knee implant. The Atlas is designed to treat osteoarthritis knee joint pain in patients ages 35 to 65 whose condition has not degenerated enough to require arthroplasty. The device is a joint unloader […]
CE Mark in hand, Moximed hatches U.S. approval strategy for knee stabilization implant
The knee replacement market has reached stratospheric levels in the U.S., with competitors ranging from Zimmer Biomet (NYSE:ZBH) to Smith & Nephew (NYSE:SNN) and Johnson & Johnson (NYSE:JNJ). California device developer Moximed is betting its future, however, on patients not quite ready for the drastic surgery. The knee replacement market is worth an estimated $4 billion […]
Moximed wins CE Mark for Atlas ‘shock absorbing’ knee
Moximed said last week it won CE Mark approval in the European Union for its Atlas ‘shock absorber’ knee joint unloader for pre-arthroplasty patients. The Atlas system is an implantable joint unloader placed subcutaneously along the knee joint to absorb excess joint load rather than transfer it to healthy areas of the joint, the Hayward, […]
Moximed springs to $33m Series B round
Moximed said today that it pulled in a $33 million Series B round for its KineSpring knee implant, which is designed to reduce the load on the joint while sparing its anatomy.
Hospital repays $2M to Medicare for unnecessary stenting | MassDevice.com On Call
MASSDEVICE ON CALL — A Pennsylvania hospital group associated with more than 140 cases of unnecessary stenting and angioplasties repaid almost $2 million in Medicare reimbursements to the federal government.
The Excela Health network reached an agreement with federal regulators to return the funds, which were collected for heart surgeries performed between 2009 and 2011, according to settlement documents made public this month.
MassDevice Network
@MassDevice
LinkedIn
YouTube